The Schwab US Dividend Equity ETF (SCHD) is recommended as a Buy for the next 12 to 24 months due to consistent dividend growth and robust portfolio diversification. Its healthcare sector allocation has increased to nearly 19%, making it a key driver and risk factor, especially around U.S. policy events. The ETF mitigates concentration risks through quarterly rebalancing and caps on stock and sector weights, maintaining an income-focused profile. The main downside risk is a potential Democratic sweep in upcoming elections, which could impact healthcare holdings, but otherwise, policy risks are manageable and mostly headline-driven.
The Schwab US Dividend Equity ETF (SCHD) shows stability with a price of USD 35.81 and a slight 1-day increase of 0.06% as of Nov 02, 2026 15:21 WIB on Pluang. This modest gain contrasts with its significant healthcare sector allocation of nearly 19%, highlighting the sector's role as both a growth driver and risk factor. With a market cap of $121.09 billion and a typical hold time of 70 days on Pluang, SCHD's performance reflects steady investor interest despite potential policy uncertainties.
The Schwab US Dividend Equity ETF (SCHD) is recommended as a strong buy due to its focus on high-quality dividends, lower exposure to volatile technology sectors, and stable cash flows. This makes it a defensive choice for retirees and cautious incom...
The article outlines a diversified dividend portfolio combining ETFs, funds, and high-yield stocks to achieve a 5.59% average dividend yield and a 6.16% annual dividend growth over five years. Key holdings include Schwab U.S. Dividend Equity ETF, Mic...
The Schwab US Dividend Equity ETF (SCHD) is popular for dividend growth but offers a modest 3% yield and lacks some diversification. Analyst Samuel Smith explains how investors can potentially more than double SCHD's yield to nearly 7% by adopting a ...
